TTFields and Chemotherapy in Metastatic Pancreatic Adenocarcinoma (mPDAC)

This study is testing whether Tumor Treating Fields (TTFields) — a wearable device that uses electrical fields to disrupt cancer cell growth — combined with a standard chemotherapy regimen can improve outcomes for patients with metastatic pancreatic cancer. **You may be eligible if...** - You are 18 or older - You have been confirmed by biopsy to have metastatic pancreatic adenocarcinoma - You have at least one tumor in the liver that can be biopsied, plus at least one other measurable tumor - Your expected survival is at least 3 months - Your general health (ECOG) is 0 or 1 - Your doctor has assigned you to receive the FOLFIRINOX chemotherapy regimen - You are willing and able to comply with all trial requirements **You may NOT be eligible if...** - Your cancer is not metastatic or has not been confirmed as pancreatic adenocarcinoma - You do not have an accessible liver lesion for biopsy - You do not have additional measurable disease beyond the biopsy site - You are not a candidate for FOLFIRINOX chemotherapy Talk to your doctor to see if this trial is right for you.